Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Betamipron is a small molecule compound, chemically known as N-benzoyl-β-alanine, used primarily as a renal protectant in combination with the carbapenem antibiotic panipenem. Its main function is to inhibit the uptake of panipenem into the renal tubule, thereby reducing nephrotoxicity associated with panipenem therapy. Betamipron acts by competitively inhibiting anionic transporters in the kidney, similar to probenecid. It has very low toxicity in mammals and is not itself an antibacterial agent but serves to enhance the safety profile of panipenem-based treatments for severe bacterial infections[1][2][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Betamipron.